Allergy Therapeutics plc

DB:HHU Stock Report

Market Cap: €362.4m

Allergy Therapeutics Management

Management criteria checks 2/4

Allergy Therapeutics' CEO is Manuel Llobet, appointed in Jul 2009, has a tenure of 15.42 years. total yearly compensation is £484.51K, comprised of 67.5% salary and 32.5% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth €379.52K. The average tenure of the management team and the board of directors is 7.3 years and 2.6 years respectively.

Key information

Manuel Llobet

Chief executive officer

UK£484.5k

Total compensation

CEO salary percentage67.5%
CEO tenure15.4yrs
CEO ownership0.1%
Management average tenure7.3yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Manuel Llobet's remuneration changed compared to Allergy Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024UK£485kUK£327k

-UK£40m

Mar 31 2024n/an/a

-UK£45m

Dec 31 2023n/an/a

-UK£50m

Sep 30 2023n/an/a

-UK£47m

Jun 30 2023UK£412kUK£342k

-UK£43m

Mar 31 2023n/an/a

-UK£36m

Dec 31 2022n/an/a

-UK£29m

Sep 30 2022n/an/a

-UK£21m

Jun 30 2022UK£665kUK£332k

-UK£14m

Mar 31 2022n/an/a

-UK£10m

Dec 31 2021n/an/a

-UK£5m

Sep 30 2021n/an/a

-UK£1m

Jun 30 2021UK£662kUK£324k

UK£3m

Mar 31 2021n/an/a

UK£5m

Dec 31 2020n/an/a

UK£7m

Sep 30 2020n/an/a

UK£7m

Jun 30 2020UK£614kUK£303k

UK£7m

Mar 31 2020n/an/a

UK£8m

Dec 31 2019n/an/a

UK£8m

Sep 30 2019n/an/a

UK£6m

Jun 30 2019UK£557kUK£295k

UK£3m

Mar 31 2019n/an/a

UK£117k

Dec 31 2018n/an/a

-UK£3m

Sep 30 2018n/an/a

-UK£5m

Jun 30 2018UK£556kUK£286k

-UK£8m

Compensation vs Market: Manuel's total compensation ($USD607.35K) is below average for companies of similar size in the German market ($USD1.02M).

Compensation vs Earnings: Manuel's compensation has increased whilst the company is unprofitable.

CEO

Manuel Llobet (59 yo)

15.4yrs

Tenure

UK£484,506

Compensation

Mr. Manuel Llobet has been the Chief Executive Officer of Allergy Therapeutics plc since July 2009. Mr. Llobet joined Allergy in September 2009 following the successful refinancing by Azure Ventures Limite...

Leadership Team

NamePositionTenureCompensationOwnership
Manuel Llobet
CEO & Executive Director15.4yrsUK£484.51k0.10%
€ 379.5k
Shaun Furlong
CFO & Executive Director1.3yrsUK£207.93k0.000030%
€ 108.7
Murray Skinner
Chief Scientific Officer9yrsno datano data
Sue Baker
Head of Human Resourcesno datano datano data
Simon Piggott
Head of Clinical Science7.3yrsno datano data
Alan Bullimore
Head of Communication & Market Developmentno datano datano data
Russell Picket
Group Financial Controllerno datano datano data
Karley Charlotte Cheesman
Company Secretary1.8yrsno datano data
Matthew Heath
Principal Scientistno datano datano data

7.3yrs

Average Tenure

Experienced Management: HHU's management team is seasoned and experienced (7.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Manuel Llobet
CEO & Executive Director15.4yrsUK£484.51k0.10%
€ 379.5k
Shaun Furlong
CFO & Executive Directorless than a yearUK£207.93k0.000030%
€ 108.7
Babatunde Otulana
Senior Independent Director7.5yrsUK£44.50k0.0010%
€ 3.8k
Peter Jensen
Chairman14.2yrsUK£94.00k0.044%
€ 159.4k
Johannes Ring
Member of Scientific Advisory Boardno datano datano data
Hendrik Kees Nolte
Chairman of Scientific Advisory Boardno datano datano data
Anthony Frew
Member of Scientific Advisory Boardno datano datano data
Lawrence Du Buske
Member of Scientific Advisory Boardno datano datano data
Anthony Parker
Non-Executive Director2yrsno data0.040%
€ 146.1k
Cheryl Macdiarmid
Independent Non-Executive Director3.2yrsUK£41.13kno data
Zheqing Shen
Non-Executive Director2yrsno data0.0019%
€ 6.8k
David William Ball
Independent Non-Executive Directorless than a yearUK£1.85kno data

2.6yrs

Average Tenure

57.5yo

Average Age

Experienced Board: HHU's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:16
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Allergy Therapeutics plc is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Adam McCarterCavendish
Patrick TrucchioH.C. Wainwright & Co.
Gary WaandersNomura Code Securities Limited